BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
3279 results:

  • 1. In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico.
    Ramírez-Santos J; Calzada F; Ordoñez-Razo RM; Mendieta-Wejebe JE; Velázquez-Domínguez JA; Argüello-García R; Velázquez C; Barbosa E
    Molecules; 2024 Apr; 29(9):. PubMed ID: 38731446
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
    Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
    PLoS One; 2024; 19(4):e0289902. PubMed ID: 38683834
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
    Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
    Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell lymphoma Cells].
    Zhang YL; Chen YH; Zheng RJ; Zheng KJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):470-475. PubMed ID: 38660854
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Noncoding RNAs in B cell non-Hodgkins lymphoma.
    Abedi Kichi Z; Dini N; Rojhannezhad M; Shirvani Farsani Z
    Gene; 2024 Jul; 917():148480. PubMed ID: 38636814
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
    Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
    Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma.
    Liang JH; Wang WT; Wang R; Gao R; Du KX; Duan ZW; Zhang XY; Li Y; Wu JZ; Yin H; Shen HR; Wang L; Li JY; Guo JR; Xu W
    Cancer Lett; 2024 Jun; 591():216877. PubMed ID: 38615930
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
    De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
    Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
    Nylund P; Nikkarinen A; Ek S; Glimelius I
    Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
    Song Y; Li J; Zhou K; Ke X; Cai Z; Zhang H; Yao T; Xia Z; Wang Y; Lai P; Liu X; Zhu J
    Leuk Lymphoma; 2024 May; 65(5):647-652. PubMed ID: 38557285
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.
    Hoang NM; Liu Y; Bates PD; Heaton AR; Lopez AF; Liu P; Zhu F; Chen R; Kondapelli A; Zhang X; Selberg PE; Ngo VN; Skala MC; Capitini CM; Rui L
    Cell Rep Med; 2024 Apr; 5(4):101484. PubMed ID: 38554704
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. BCL-2 inhibition in haematological malignancies: Clinical application and complications.
    Fowler-Shorten DJ; Hellmich C; Markham M; Bowles KM; Rushworth SA
    Blood Rev; 2024 May; 65():101195. PubMed ID: 38523032
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Wolska-Washer A; Robak P; Witkowska M; Robak T
    Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
    Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
    Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
    Soumerai JD; Diefenbach CS; Jagadeesh D; Asch A; Kumar A; Tsai ML; Jandl TA; Lossos IS; Kenkre VP; Awan F; Novotny W; Huang J; Miao L; Rajagopalan P; Ghalie RG; Zelenetz AD
    Br J Haematol; 2024 May; 204(5):1762-1770. PubMed ID: 38500476
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma.
    Zhang T; Wang ZT; Li Z; Yin SX; Wang X; Chen HZ
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):120. PubMed ID: 38466431
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
    Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
    Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell lymphoma.
    Lymphoma Research Foundation LRF
    Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 164.